Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis
| Autor: | Lital Abraham, Anat Achiron, Alex I. Halpern, Ofir Zmira |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Expanded Disability Status Scale Neurology business.industry Multiple sclerosis General Medicine Disease medicine.disease 03 medical and health sciences 0302 clinical medicine Tolerability Internal medicine Cohort medicine Alemtuzumab 030212 general & internal medicine Neurology (clinical) business Adverse effect 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Acta Neurologica Belgica. 121:1513-1518 |
| ISSN: | 2240-2993 0300-9009 |
| Popis: | Alemtuzumab is a monoclonal anti-CD52 antibody prescribed to treat relapsing–remitting multiple sclerosis (RRMS). Alemtuzumab affects the balance of the immune system by depleting circulating lymphocytes, leading to the formation of a new immune repertoire less likely to induce autoimmune attack against CNS myelin. We collected real-world data of RRMS patients treated with alemtuzumab. We assessed relapse rate, disability progression, and MRI-related disease activity over a 24 month period. Our study included 35 RRMS patients (19 female and 16 male) with a mean age of 37.3 years (SD = 10.5). The patient cohort had a mean disease duration of 10.4 years, median previous disease modifying treatments (DMTs) of 3.0, and a median expanded disability status scale (EDSS) score of 4.0 (IQR 2.5–6.0). Neurological disability remained stable during treatment and there was no statistically significant change in EDSS score. Prior to treatment, the median relapse rate was 2.0 (IQR 1.0–3.0); after treatment the median relapse rate was 0.0. This 2.0 decrease in relapse rate is statistically significant (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink